- LOGIN
- MemberShip
- 2026-04-12 22:51:50
- Company
- GC Pharma & SK Bioscience are competing
- by Ji Yong Jun Feb 16, 2022 05:51am
- From the left, GC Pharma Barycela and SK BioscienceGC Pharma's Barycela challenges the international procurement market. Competition among domestic companies in the international procurement market for chickenpox virus vaccines is likely to begin in earnest. SK Bioscience seems to be challenging first while undergoing the World Health Organization (WHO) certification process for overseas sales of GC Pharma's new chickenpox vaccine. According to the industry on the 15th, SK Bioscience made its debut in the international procurement market for chickenpox vaccines on the 14th. SK Bioscience received a preliminary notice from PAHO about $31.27 million worth of chickenpox vaccine orders. SK Bioscience will supply Sky Varicella, a chickenpox vaccine, to the Latin American market from 2022 to 2024. PAHO, along with UNICEF, is the largest vaccine consumer. SK Bioscience plans to introduce Sky Varicella to various international procurement markets in the future as it passes the PAHO bid. Sky Varicella was released in 2018. In multinational global clinical trials, including Latin America, immunity and effectiveness in children aged 12 months to 12 years have been confirmed. The chickenpox vaccine from global pharmaceutical companies was used as a control group to prove the level of safety equivalent to that of excellent antibodies. As a result, SK Bioscience and GC Pharma competed in the chickenpox vaccine international procurement market. GC Pharma has dominated the international procurement market with Suduvax. Suduvax is the first vaccine developed by GC Pharma in 1993 in Korea and the second in the world. Suduvax, which has won bids in the international procurement market, has served as GC Pharma's cash cow. From 2017 to 2018, it won about $60 million worth of orders from PAHO, ranking first in the procurement market. Chickenpox vaccines generate more sales in overseas markets than in Korea. As a result, domestic companies actively utilize the international procurement market to advance the vaccine into the global market. According to Allied Market Research, a global market research firm, the global chickenpox vaccine market is expected to grow 5.6 percent annually from $2.714 billion in 2018, forming a scale of $4.22 billion by 2026. GC Pharma will also challenge the international procurement market within this year through Barycela. Barycela was approved by the MFDS in March 2020 and was released in Korea in September last year. Like Suduvax, Barycela is a live vaccine and it has improved quality and productivity, greatly increasing yields. GC Pharma's Barycela is currently undergoing WHO PQ certification process. PQ certification is essential to participate in bidding for the international procurement market. The industry predicts that Barycela will acquire PQ certification and participate in the international procurement market in the first half of this year.
- Company
- Amgen’s Lumakras approved in Korea… first-ever approved
- by Feb 16, 2022 05:51am
- Amgen Korea announced on the 15th that the Ministry of Food and Drug Safety approved its ‘Lumakras (sotorasib)’ for the treatment of KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer on the 15th. Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. With the approval, Lumakras became the first targeted therapy to be approved by the MFDS for KRAS G12C NSCLC patients. KRAS is one of the major oncogenes that is found in various cancers including NSCLC. It is the second-most common mutation that occurs in Asian patients after EGFR mutations. NSCLC patients with the KRAS G12C mutation have shown a lower relative survival rate than other lung cancer patients in surgery or chemotherapy, as many are resistant to existing standard therapies. Lumakras is the first-ever oral treatment that selectively inhibits the KRAS G12C mutant protein that is involved with the development of lung cancer. It inactivates the KRAS G12C mutant protein that promotes tumor growth and effectively blocks the signaling for oncogenic activity without affecting the wild-type KRAS. The MFDS approval was based on the phase-1/2 CodeBreak 100 trial results conducted on 124 NSCLC patients confirmed with locally advanced or metastatic NSCLC with KRAS G12C mutations. Patients who participated in the trial had been previously treated with chemotherapy or immunotherapy but experienced recurrence. Results showed that the objective response rate, including complete remission and partial remission, was 36%. Tumor shrinkage was observed in 82.3% of the patients, and the median maximum tumor shrinkage rate of the patients was consistently high at 60%. Professor Myung Ju Ahn from the Samsung Medical Center said, “KRAS G12C-mutated NSCLC was an area where a dire need remained for a new treatment option. The average progression-free survival period of these patients had been around 4 months despite the use of chemotherapy and immunotherapy treatment, and no targeted therapy option was available, unlike other mutations. The domestic approval of Lumakras, the first targeted therapy for KRAS G12C mutated NSCLC, is long-awaited news for both the patients and HCPs in the field. Based on its excellent treatment effect and safety profile confirmed in clinical trials, Lumakras is expected to greatly contribute to improving the prognosis of patients."
- Policy
- There's plenty of COVID-19 PO medicine, Regkirona
- by Lee, Jeong-Hwan Feb 16, 2022 05:51am
- The quarantine authorities said they have secured sufficient supplies of COVID-19 oral treatments in Korea and will continue to consider additional purchases depending on the quarantine situation. The quarantine authorities also said they would consider using the budget for purchasing Regkirona as an oral drug as Regkirona, an antibody treatment for COVID-19, is known to be vulnerable to responding to Omikron mutations. On the 14th, the KDCA responded in writing to the National Assembly's Health and Welfare Committee's Seo Young-seok of the Democratic Party and Lee Jong-sung of the People's Power. Rep. Seo asked if it was possible to secure PO drugs such as Paxlovid and expand the number of additional prescriptions. He also inquired about plans to expand the pharmacy in charge. The KDCA replied that it has pushed for a purchase contract for 1,044,000 people in consideration of the spread of Omicron and the quarantine situation. The KDCA has signed a purchase contract Pfizer vaccine (for 762,000 people) and MSD vaccine (for 242,000 people). The KDCA also said it will continue to consider the need for purchase by comprehensively considering the quarantine situation, medical response, development status of domestic and foreign treatments, and clinical efficacy. The KDCA explained that it has been steadily expanding and operating prescription agencies and pharmacies in charge after bringing PO drugs into Korea on the 14th of last month, and that the criteria for those subject to administration have also been expanded. The KDCA replied, "We will continue to improve for a stable supply so that the treatment to be eaten can be administered quickly and safely to those who need it." Rep. Lee Jong-sung said that the budget set for the purchase of Regkirona, an antibody treatment, should be changed to the budget for additional purchase of oral drugs effective in omicron mutations.bThe KDCA agreed with Rep. Lee and replied that it would consider ways to use Regkirona's purchase cost for oral medicine. Specifically, the KDCA set aside 393.3 billion won in the main budget this year, and 3.4 billion won in the purchase of Regkirona. As a result of the Regkirona pharmacological test on mutants, it was evaluated that they were less likely to show activity in omicron mutations, so they should be careful when prescribing them. Accordingly, the KDCA plans to allow the purchase of Regkirona to be used as the purchase of PO drugs in response to Omikron. The KDCA said, "We have not yet signed a contract for Regkirona purchase cost of 3.4 billion won this year," and added, "We will consider securing PO treatments effective for Omicron mutations."
- Company
- The paradox of COVID-19
- by Kim, Jin-Gu Feb 15, 2022 05:54am
- In contrast to the intensifying supply and demand difficulties of cold medicine and the decline in the performance of respiratory Rx drugs such as antibiotics and expectorants. After the transition to COVID-19 home treatment, the shortage phenomenon intensified, and the pharmaceutical industry began to "excess production." Demand for OTC cold medicines is soaring due to the spread of Omicron mutations. Some pharmaceutical companies have begun overproduction to expand supply. OTC was out of stock This is in contrast to the prolonged slump in Rx drugs such as antibiotics and expectorants used in respiratory infectious diseases. The Corona crisis is acting as a boom in the OTC market and a recession in the Rx drug market. ◆ The shortage of OTC cold medicine and pharmaceutical industry has started overproduction According to the pharmaceutical industry on the 14th, the shortage is prolonged in front-line pharmacies, focusing on commercial medicines such as cold medicines and fever reducers. In particular, general medicines such as Theraflu, Coldaewon, and Champ are mostly out of stock at online malls. In fact, an official from Ildong Pharmaceutical, who is in charge of domestic sales of Theraflu, said, "It is difficult to confirm accurately due to the lack of statistics in February, but demand seems to have doubled or tripled than usual." An official from Dong-A Pharmaceutical, who is producing and supplying the children's fever reducer and cold medicine Champ series, also said, "The demand for the first and second weeks of February has soared. We are continuing to produce, but at the moment, we are unable to keep up with demand." He said, "Not only cold medicine, but also liquid painkillers Ibuone-Q, DexoneQ, and Nap OneQ have more than doubled their sales than usual. Morgle One Q, a treatment for sore throat symptoms, and Noseone Q, a treatment for rhinitis symptoms, are also sold more than usual, he said. Pharmaceutical companies that are supplying related products are focusing on expanding production. In particular, it is also confirmed that some pharmaceutical companies have started overproduction to increase supply. An official from Daewon Pharmaceutical, which is selling the OTC Coldaewon series, said, "We are trying to expand production as demand increases rapidly in the field," adding, "In the production plant, the people in charge are even working overtime." The pharmaceutical industry believes that demand for OTC cold medicines and fever reducers has soared before and after the government announced a change in COVID-19 quarantine and treatment guidelines. Analysts say that more and more consumers are trying to prepare OTC cold medicine as a regular medicine to prepare for Omicron mutations. Theaflu, Champ, and Coldaewon are all out of stock Since the 10th, the government has implemented a new quarantine and home treatment system tailored to the characteristics of Omicron's COVID-19 mutation. The main point is that patients under the age of 60 with asymptomatic or mild symptoms should take care of their health on their own without government care. ◆The use of Rx drugs such as antibiotics and spectators used for respiratory symptoms such as is greatly decreasing Although drugs are used for the same respiratory symptoms, they are in contrast to the significant contraction of the prescription drug market such as flu treatments, antibiotics, and spectators. According to UBIST, a pharmaceutical market research firm, the amount of outpatient prescriptions for flu treatments last year was only 46 million won. It is significantly different from 22.5 billion won in 2019 and 8.8 billion won in 2020. In fact, it is evaluated that the flu treatment market has disappeared. The flu treatment has undergone the most dramatic change since the spread of COVID-19. After the spread of COVID-19, the number of flu patients dropped sharply due to strengthening personal hygiene management such as washing hands and wearing masks. The same is true of changes in sales of antibiotics. Last year, the amount of outpatient prescriptions for oral Cephalosporins was 194.6 billion, down 8.0% from the previous year. It fell 28.2% from 27.1 billion won in 2020. Cephalosporin drugs, also called Cepha, are widely used for pneumonia, sore throat, tonsillitis, and bronchitis. Last year, the prescription size of oral PCN was 105.2 billion won, down 15.7% from the previous year. It decreased 40.8% in two years from 182.2 billion won in 2019, before the COVID-19 outbreak. An official from the pharmaceutical industry said, "The sluggish prescription market for infectious disease diseases is prolonged due to the prolonged COVID-19, but paradoxically, the OTC market is booming due to the surge in COVID-19 confirmed patients."
- Company
- Drug pricing negotiations for ‘Xospata’ complete
- by Eo, Yun-Ho Feb 15, 2022 05:54am
- The new leukemia drug ‘Xospata’ has crossed the final barrier to reimbursement in Korea. According to industry sources, Astellas Pharma Korea completed drug pricing negotiations for its acute myeloid leukemia (AML) treatment Xospata (gilteritinib) with the National Health Insurance Service. Accordingly, if the agenda passes the Health Insurance Policy Deliberative Committee meeting in February, Xospata may be reimbursed from the following month (March). Astellas has opted for the pharmacoeconomic evaluation exemption track to receive reimbursement for Xospata and therefore will be reimbursed under the Expenditure cap type of the Risk Sharing Agreement (RSA). The drug, which was approved in March 2020, has passed the National Health Insurance Service’s Drug Reimbursement Evaluation Committee in September last year and started negotiations with the NHIS in the same year. After failing to reach an agreement within the set negotiation period (60 days), the company was finally able to reach an agreement this time after extending the deadline once. Interest in Xospata’s reimbursement is high as such a treatment option has not existed before. The Korea Alliance of Patients' Organization had delivered its position requesting the rapid reimbursement of new drugs including Xospata at the meeting with the Ministry of Health and Welfare’s Division of Pharmaceutical Benefits. Hui-Jae Kim, Professor of Hematology at Seoul St.Mary’s Hospital said, “Xospata’s approval relieved AML patients of the specific anxiety of having to suffer their condition without a proper treatment available. Of course, its cost remains an issue, but I expect the drug to quickly settle as the standard of care after being listed for reimbursement.” Meanwhile, Xostapa is the first FLT inhibitor approved by the MFDS for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation (FLT3mut+). The drug targets both types of FLT3 mutations, FLT3-ITD and FLT3-TKD, and can be self-administered at home as a single oral tablet once daily without frequent hospital visits. Also, Xostapa has improved efficacy compared with existing chemotherapy. In addition, Xostapa has received a ‘Category 1’ recommendation for patients with relapsed or refractory AML with an FLT3 mutation in the latest NCCN Clinical Practice Guidelines.
- Company
- The next Saxenda? Companies race to occupy GLP-1 RA market
- by Feb 15, 2022 05:54am
- GLP-1 class drugs are taking over the obesity treatment market. With ‘Saxenda’ in the lead, pharmaceutical companies in Korea and abroad are racing to catch up with Novo Nordisk, while the company is working to bring another improved GLP-1 analogue into the market. According to industry sources on the 14th, pharmaceutical companies in Korea and abroad are busy developing obesity treatments using GLP-1 analogues. Lilly is spurring up the development of its product in the market currently occupied by Novo Nordisk, with Hanmi Pharmaceutical and Humedix in Korea also conducting research. ◆Novo Nordisk spurs up development of an improved product based on Saxenda’s success Novo Nordisk is conducting domestic clinical trials for the injection-type and oral-type formulation of its long-acting GLP-1 analogue, ‘semaglutide.’ For the semaglutide injection that was approved in September, a Phase IIIb clinical trial is being conducted on 150 Asians with the Body Max Index (BMI) standard set at ‘25㎏/㎡or higher’ in line with the local obesity standard. The semaglutide injection being studied is ‘Wegovy,’ which has been approved by the US FDA in June last year. Then in November of the same year, a Phase IIIa trial was approved for an oral formulation of the injected semaglutide on 198 overweight or obese East Asians. The oral semaglutide is the first modified GLP-1 analogue formulation made by Novo Nordisk. The drug was approved by the US FDA as ‘Rybelsus’ in September 2019 and is being reviewed for approval in Korea as a diabetes treatment. Previously, Novo Nordisk had made a breakthrough in the obesity treatment market with its GLP-1 analogue. The company had changed the dosage of its GLP-1 analogue ‘Victoza’ that is used to treat diabetes and transformed it into the obesity treatment ‘Saxenda.’ Immediately upon its release, Saxenda rose to the top in the domestic obesity treatment market in 2018. In only 2 years since the release, its sales exceeded 30 billion won. According to the pharmaceutical research institute IQVIA, Saxenda’s sales recorded 36.8 billion won in 2020. Before Saxenda, ‘Belviq (lorcaserin)' and phentermine and phendimetrazine class antipsychotics were commonly used to treat obesity. Among these drugs, Belviq withdrew from the market, and sales of ‘Qsymia’ that combined phentermine and topiramate have surged recently. The reason why Saxenda gained popularity despite being an injection was in its relatively less amount of side effects. Drugs that had previously led the obesity treatment market were banned due to safety issues. ‘Reductil (sibutramine)’ and ‘Belviq (lorcaserin)’ have both withdrawn from the market due to cardiovascular and carcinogen risk. Patients are also required to exercise caution in the long-term use of antipsychotics like phentermine and phendimetrazine due to the risk of CNS side effects such as depression and insomnia. A Novo Nordisk official said, “Developing an obesity treatment is more difficult than other chronic diseases because maintaining the lost weight is as difficult as losing the weight. Novo Nordisk aims to close the gap between anti-obesity drugs and metabolic surgery through long-acting, combination drugs, etc.” ◆Lilly fiercely chases Novo Nordisk… Hanmi attempts at a winning bid with 'efpeglenatide' Lilly, which had been at the forefront of the race in developing GLP-1 analogues in diabetes, is at the other end of the race and is chasing Novo Nordisk in the obesity treatment market. This is because Lilly’s long-acting once-weekly GLP-1 analogue ‘Trulicity’ has a stronghold over the diabetes treatment market but does not own an indication for treating obesity. As a result, Lilly is looking to overtake the obesity treatment market with its next-generation GLP-1 analogue, its dual GIP, and GLP-1 receptor agonist ‘tirzepatide.’ GIP is a hormone that stimulates insulin secretion that works with GLP-1 to increase the weight loss effect. Tirzepatide’s diabetes indication is anticipated to be approved within this year by the US FDA. The drug has ranked No.2 among most-marketable drugs this year that was selected by the global biopharmaceutical market research institution, Evaluate Vantage. Domestic pharmaceutical companies have also jumped into the competition. Hanmi Pharm intends to apply its once-weekly administered GLP-1 class 'efpeglenatide' to obesity as well as diabetes. Currently, the company completed a global phase III trial for efpeglenatide on patients with diabetes or cardiovascular disease. Although slow to enter the competition, Humedix also started developing its own GLP-1 analogue. Humedix has signed an agreement with HLD to jointly research and develop a long-lasting injection for obesity treatment in August last year. Yuhan Corp is also developing a GDF15 inhibitor to compete with GLP-1 analgogues. Its candidate drug YH34160 binds specifically the GDF15 receptor that is mainly present in the brain to induce weight loss through appetite suppression. The company plans to complete the preclinical toxicity test on YH34160 within the year.
- Company
- Takeda, Boehringer, & AZ were selected as the Best Companies
- by Eo, Yun-Ho Feb 15, 2022 05:53am
- .Three Korean subsidiaries have been selected as the 2022 Global Top Employment Company. Boeringer Ingelheim, and AstraZeneca Korea were selected as "the best hiring companies" by setting extraordinary efforts and examples for welfare and employee competency development. Among them, Takeda was listed by Korean subsidiaries for the sixth consecutive year, and Beringer Ingelheim and AstraZeneca for the third consecutive year. Takeda received positive reviews every year for supporting various programs for employee competency development, such as strength-based coaching culture and horizontal open communication. Boeringer Ingelheim's headquarters has also been selected as one of the world's top 11 employment companies this year for the second consecutive year, and has also been certified as the best employment company in the Asia-Pacific region (ASEAN, Korea, Australia, and New Zealand). In the case of AstraZeneca, it received high scores in terms of flexible performance evaluation and reward system, online and offline hybrid working environment designed to enable smooth two-way communication, and diversity and inclusive culture. Meanwhile, the world's best employment company is organized by "horizontal open communication," a world-class personnel management evaluation agency, and annually surveys employment status and discloses a list of companies. In order to be certified as the "global best employment company," it must be certified as a "top employee" at branches in more than 20 countries in four regions, including the company's global headquarters.
- Company
- Changes in sales and marketing of companies
- by Moon, sung-ho Feb 15, 2022 05:53am
- As the COVID-19 pandemic continues for more than three years, changes are also taking place in academic sales and marketing of pharmaceutical companies. Pharmaceutical companies are competitively holding events for doctors on a rich theme and scale comparable to academic conferences of medical associations. This is a self-rescue measure due to the decrease in promotional activities, such as the prolonged COVID-19 and the transition of academic conferences to online conferences. According to the medical and pharmaceutical industries on the 10th, it was confirmed that more and more domestic pharmaceutical companies are holding large-scale "online symposiums" reminiscent of major medical conferences. The first case of introducing this is Dong-A ST's Korea Disease Week (KDW). It looks like an academic conference held by major domestic academic societies, but it is an online symposium held by Dong-A ST itself. In terms of size, it is as good as the academic conferences of existing academic societies. The period lasted for a week, and in addition to existing chronic diseases such as high blood pressure and diabetes, various experts related to cardiovascular disease were invited to form a large-scale academic feast, which received great response last year. When the KDW was held last year, an average of 2,100 doctors per day and a total of 10,500 doctors participated in the event. It is said that it was much more than the number of people participating in the general academic conference event. Dong-A ST is pushing for its second hosting in June. Domestic pharmaceutical companies such as Daewoong Pharmaceutical and Daewon Pharmaceutical are also competitively striving to hold online symposiums for their own doctors. In the case of Daewon Pharmaceutical, an academic event was held under the name AGORA WEEK in a similar way to Dong-A ST's KDW, while Daewoong Pharmaceutical also decided to hold an academic event for doctors under the name of Dowong Medical Festival (DMF). Another common point is that they are trying to expand the area of "online platform" for their doctors by holding such large-scale academic events. In particular, Daewon Pharmaceutical has a strong purpose of promoting the operation of an online platform (D·Talks, Detox) for doctors earlier this year. Likewise, Mediflicks and Doctorville use their own operating online platforms in common. At the same time as the academic symposium is held, the video is provided so that doctors can check it at any time by using the platform themselves.
- Company
- The era of personalized healthcare has arrived
- by Eo, Yun-Ho Feb 14, 2022 05:54am
- Optimal treatment for each patient differs by one’s genetic mutation. With this discovery, anticancer therapies targeting individualized genes have emerged one after another, and the field of precision medicine is evolving from ‘disease-targeted’ to ‘gene-targeted’ prescriptions. In particular, anticipation in the field is rising with the nearing possibility of prescribing NTRK(Neurotrophic tyrosine receptor kinase) inhibitors and the introduction of RET-targeted therapies in Korea. ◆'Rozlytrek ' and 'Vitrakvi' Roche Korea’s 'Rozlytrek (entrectinib)’ and Bayer Korea’s ‘Vitrakvi (Larotrectinib)’ are undergoing processes to receive insurance benefits in Korea. These two drugs, which are aiming to receive reimbursement through the pharmacoeconomic evaluation exemption track, have passed deliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee last year but are yet to reach an agreement with the NHIS in their drug pricing negotiations. The drugs are indicated for the treatment of adult and pediatric patients who have an NTRK gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; have either progressed following treatment or have no satisfactory alternative therapy. In other words, the drugs may be used in most NTRK gene fusion-positive solid tumors. Roche and Bayer are generating prescription codes for their drugs at major medical institutions to allow the drugs to be prescribed immediately upon reimbursement. ◆'Gavreto' and 'Retevmo' Rozlytrek’s developer Roche is also undergoing the approval process for its other tumor-agnostic therapy 'Gavreto (pralsetinib),’ and Lilly Korea for its 'Retevmo (selpercatinib).’ The two drugs are expected to be approved within the year. The drugs, which target RET(Rearranged during transfection) gene fusions, inhibit the primary as well as the secondary mutation that causes resistance to anticancer treatments and are expected to address the unmet needs in various cancers. Retevmo, which had been quicker, became the first-ever RET inhibitor to receive approval. Retevmo was approved in May 2020, and Gavreto in September of the same year by the US FDA. Retevmo was approved for the two indications of non-small cell lung cancer (NSCLC) and thyroid cancer. Gavreto was initially approved as a treatment for lung cancer, then added a thyroid cancer indication in December of the same year. Although the drugs were initially approved for lung cancer and thyroid cancer, the companies plan to further increase the scope of indications for their RET inhibitors. RET gene fusion is discovered rarely in colorectal cancer, breast cancer, pancreatic cancer, and EGFR-mutant NSCLC. Gavreto and Retevmo are also expected to take the PE exemption track to receive reimbursement listing in Korea. Kyong-Hwa Park, Professor of Hemato-Oncology at Korea University Anam Hospital said, “There needs to be a reimbursement track established for precision medicine in Korea. I can’t imagine the distress and deprivation the patients would feel if a precision medicine drug is available with NGS screening but cannot be accessed due to systemic issues."
- Opinion
- [Reporter's view]Predictability should be increased
- by Lee, Tak-Sun Feb 14, 2022 05:54am
- Starting with Choline Alfoscerate, a brain function improving agent, the benefit reassessment, which has been in full swing since last year, has risen again this year. On the 11th, HIRA's Drug Reimbursement Evaluation Committee confirmed the items subject to salary revaluation in 2022 and 2023. Detailed items will be released through the Health Insurance Policy Committee. However, despite the HIRA notice, the target item was released to the media a few hours later. Six drugs, including Godex, were included in 2022 and eight drugs, including Hyaluronic acid eye drops, in 2023. Since media reports, the HIRA has not made any opinions on this. Perhaps this is because the items subject to re-evaluation match. Rather, they seem to be more curious about how the target item was delivered to the media. The exposure of items is due to the constant intelligence activities of the pharmaceutical industry to know the subject of re-evaluation in advance. No matter how much the HIRA cracks down on subcommittees or groups of experts in the committee that deliberate on revaluation targets, it is interpreted that it has not overcome the pharmaceutical industry's desire to predict revaluation projects in advance. This is because the benefit revaluation project is piled up in the veil. When The HIRA announced its five-year revaluation plan last year, it said it would use ▲ 0.1% of claims, or more than 20 billion won ▲ less than one of A8 countries, ▲ policy and social demands, insufficient intellectual drugs ▲ other committees. On top of that, there is an opinion that the registration date may have been considered. However, it is difficult to predict target items based on these criteria. Rather, looking at the selected drugs, most of them have undergone clinical re-evaluation by the MFDS or controversy over their socially usefulness. In fact, it is difficult to predict the order of re-evaluation. From a pharmaceutical company's point of view, if they knew the order of re-evaluation of benefits a few years ago, they would decide whether to maintain the business of the item and develop a new business to replace it. However, if it is announced so suddenly, companies cannot afford to prepare. Therefore, it may be a natural choice for companies to continue lawsuits such as suspension of execution. In order to increase predictability, the HIRA plans to disclose items subject to re-evaluation not only this year but also next year. Accordingly, the items subject to next year's re-evaluation have gained time to prepare for now. However, there is a limit to enhancing the predictability of the business by disclosing only the target items for next year. For now, it is not known whether the project will continue in the long run or end up with five years. If it is carried out regularly, how about applying a renewal system like the MFDS to determine whether or not to reevaluate benefits according to the order of registration date? In addition, if it was a five-year temporary project, the predictability of pharmaceutical companies would have increased if it had been divided by disease in the first place. The revaluation in this way is much more unilateral. Rather, the predictability of the business should be increased, giving the company more time to prove the clinical usefulness of the drug. Although it is a burden on health insurance finances, it is still important that drugs necessary for patients are not expelled due to lack of data evidence. It is questionable whether this will be properly filtered out by a short-term re-evaluation.
